Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
WuXi Biologics sells vaccine plant as new U.S. law looms
The Chinese drug services giant built an Irish factory to produce vaccines for Merck, but has now opted to sell the plant to the U.S.-based multinational for $500 million Key…
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
Leading pharmaceutical research outsourcing company WuXi AppTec Co. Ltd. (2359.HK; 603259.SH), announced on Tuesday that it has agreed to transfer its entire equity stakes in Advanced Therapies and Oxford Genetics…
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
Market talk is swirling that WuXi AppTec may be preparing to shed its cell and gene therapy business to limit potential exposure to U.S. biosecurity legislation Key Takeaways: The drug…
Kindstar Globalgene finds bargain in solid tumor testing acquisition
The testing services provider’s proposed $31.3 million purchase price for AnchorDx represents a heavy discount to the company’s earlier valuations Key Takeaways: Kindstar Globalgene’s proposed acquisition of AnchorDx would allow…
Recent Articles
RELATED ARTICLES
-
WuXi group wrestles with uncertainty over pharma tariffs
- Huge Dental hopes Hong Kong smiles on its latest listing attempt
- Medtide launches IPO to bulk up its weight-loss business
- 3SBio hits the big time with $6 billion cancer drug deal
- Joinn Labs undermined by AI as FDA phases out animal drug testing
